"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...

Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...

Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 Meiji Seika Pharma Co., Ltd. (Headquarters ...